NCT04594642 - A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

317

Participants

Timeline

Start Date

March 2, 2021

Primary Completion Date

April 19, 2028

Study Completion Date

April 19, 2028

Conditions

B-cell Non Hodgkin LymphomaDiffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma

Interventions

DRUG

AZD0486 IV

AZD0486 is a bispecific antibody targeting CD19 on tumor cells and CD3 on T-cells leading to T cell-mediated cytotoxicity of malignant B cells

Trial Locations (27)

333

RECRUITING

Research Site, Kweishan

704

RECRUITING

Research Site, Tainan City

3004

RECRUITING

Research Site, Melbourne

3084

RECRUITING

Research Site, Heidelberg

5042

NOT_YET_RECRUITING

Research Site, Bedford Park

7000

RECRUITING

Research Site, Hobart

10002

RECRUITING

Research Site, Taipei

15237

RECRUITING

Research Site, Pittsburgh

28204

RECRUITING

Research Site, Charlotte

33612

RECRUITING

Research Site, Tampa

40207

RECRUITING

Research Site, Louisville

43210

RECRUITING

Research Site, Columbus

53226

RECRUITING

Research Site, Milwaukee

77030

RECRUITING

Research Site, Houston

78704

RECRUITING

Research Site, Austin

97239

WITHDRAWN

Research Site, Portland

833401

RECRUITING

Research Site, Kaohsiung City

08901

RECRUITING

Research Site, New Brunswick

104-0045

RECRUITING

Research Site, Chūōku

135-8550

RECRUITING

Research Site, Kōtoku

460-0001

RECRUITING

Research Site, Nagoya

990-9585

RECRUITING

Research Site, Yamagata

03080

RECRUITING

Research Site, Seoul

05505

RECRUITING

Research Site, Seoul

06351

RECRUITING

Research Site, Seoul

06591

RECRUITING

Research Site, Seoul

120-752

RECRUITING

Research Site, Seoul